The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866.
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Merck; NCCN; Nektar; Seagen
Research Funding - BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Gary D. Steinberg
Honoraria - AstraZeneca; Baxter; BioCancell; Bristol-Myers Squibb; CG Oncology; Epivax Oncology; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Heat Biologics; Janssen Oncology; MDxHealth; Merck; Natera; Photocure; Roche/Genentech; Sesen Bio; Taris Biomedical; Telesta Therapeutics; Urogen pharma
Consulting or Advisory Role - Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; MDxHealth; Merck; Natera; photocure; Roche/Genentech; Taris BioMedical
 
Jens Bedke
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Research Funding - Bristol-Myers Squibb (Inst); MSD; Roche (Inst)
 
Hiroyuki Nishiyama
No Relationships to Disclose
 
Xiao Fang
Employment - Merck
 
Ritesh Kataria
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Blanca Homet Moreno
Employment - Merck Sharp & Dohme
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Research Funding - Merck Sharp & Dohme; Merck Sharp & Dohme (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)